Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-1553 + IN10018 in KRAS G12C-mutated advanced solid tumors
CTR20222034Phase 2Terminated
- Sponsor
- EpimAb Biotherapeutics
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of garsorasib and ifebemtinib in Nonhematologic neoplasms, sponsored by EpimAb Biotherapeutics. Primary endpoints: Treatment-emergent adverse events (AEs) in phase Ib, Dose-limiting toxicities (DLTs) in phase Ib and 1 more. Started Aug 2022; status: terminated.
02
Drugs
garsorasibifebemtinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20222034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222034.